HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

NCT06125314 · clinicaltrials.gov ↗
COMPLETED
Status
517
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AstraZeneca